The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models

Abstract

Pancreatic adenocarcinomas are aggressive and frequently develop resistance to all current therapies. Replication-selective adenoviruses can overcome resistance to chemotherapeutics through their sensitizing effects on drug-induced cell killing. We previously found that adenovirus deleted in the anti-apoptotic E1B19K gene enhanced gemcitabine-induced apoptotis. Here we demonstrate that our engineered double-deleted AdDD mutant (deleted in the pRb-binding E1ACR2 region and E1B19K) selectively replicates and enhances cell killing in combination with DNA-damaging cytotoxic drugs in pancreatic cancer cells. Combinations of AdDD with gemcitabine, irinotecan or cisplatin resulted in two-to fourfold decreases in EC 50 (half maximal effective concentration) values and was more efficent than similar combinations with wild-type virus, the dl1520 (ONYX-015) and dl922-947 mutants. AdDD replication was impaired in normal bronchial human epithelial cells and did not sensitize the cells to drugs. Gemcitabine-insensitive AsPC-1, BxPC-3 and PANC-1 cells were efficiently killed by irinotecan in combination with AdDD. Suboptimal doses of AdDD and gemcitabine significantly prolonged time to tumor progression in two human pancreatic tumor xenograft in vivo models, PT45 and SUIT-2. We conclude that AdDD has low toxicity to normal cells while potently sensitizing pancreatic cancer cells to DNA-damaging drugs, and holds promise as an improved therapeutic strategy for pancreatic cancer.

Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT‑2 pancreatic cancer mouse model

“…The SUIT-2 orthotopic pancreatic cancer mouse model has been used in other studies for evaluating promising new anticancer agents (14,(17)(18)(19)(20) evaluated the tumor reduction effects by measuring tumor weight in a mouse model. SUIT-2 is reported not only in an orthotopic but also in a subcutaneous model, a peritoneal dissemination model, and a lung metastasis model.…”

Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics

“…Adenoviruses are also being developed that incorporate multiple gene deletions, further increasing the selectivity towards cancerous cells. Importantly, these viruses have been shown to remain equally efficacious in addition to having increased selectivity with multiple deletions (26,27).…”

Novel diagnostic and therapeutic modalities using endoscopic ultrasound in pancreatic disease

“…72 More recent studies have used ONYX-015 in pancreatic models, but to date there are no randomized clinical trials evaluating this agent's efficacy. 73 Tumor necrosis factor erade Tumor necrosis factor (TNF) erade (GenVec, Gaithersburg, MD, USA) is a second-generation replication-deficient adenovector that expresses the TNF-alpha gene, which is regulated by a chemotherapy and radiation-inducible promoter. Injection of TNFerade directly into tumor cells allows delivery of TNFalpha via gene transfer.…”